Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26696497 | 0.81 | EPHX2 (0.55) | EPHX2CA12CA2CA7CA9 | |
| SCHEMBL9245622 | 0.78 | EPHX2 (0.58) | EPHX2CA12CA2CA7CA9 | |
| SCHEMBL9975557 | 0.78 | CNR2 (0.60) | FAAH | |
| SCHEMBL1758641 | 0.77 | EPHX2 (0.50) | EPHX2CA12CA2CA7CA9 | |
| SCHEMBL18102165 | 0.76 | MGLL (0.55) | FAAHALOX5OXER1NR1I2PGR | |
| SCHEMBL17399522 | 0.74 | ADORA3 (0.54) | FAAHEPHX2ALOX5OXER1NR1I2 | |
| SCHEMBL19387708 | 0.74 | ADORA3 (0.54) | FAAHEPHX2ALOX5OXER1NR1I2 | |
| SCHEMBL2425661 | 0.73 | TSHR (0.67) | EPHX2ALOX5OXER1NR1I2PGR | |
| SCHEMBL2425660 | 0.73 | TSHR (0.67) | EPHX2ALOX5OXER1NR1I2PGR | |
| SCHEMBL15385465 | 0.73 | MGLL (0.56) | FAAHEPHX2ALOX5OXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202893-B2 | Cannabinergic lipid ligands | UNIVERSITY OF CONNECTICUT (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202893-B2 | Cannabinergic lipid ligands | UNIVERSITY OF CONNECTICUT (US) | 2012-06-19 | — | — | US | disclosed |
| US-20090163557-A1 | Cannabinergic Lipid Ligands | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-25 | — | — | US | disclosed |
| US-20090163557-A1 | Cannabinergic Lipid Ligands | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163557-A1 | Cannabinergic Lipid Ligands | FAAH, FAAH2, CNR2 | FAAH 1/4885EPHX2 681/4885ALOX5 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.